Laupheim, Germany, January 30, 2011 / B3C newswire / - Rentschler Biotechnologie GmbH is pleased to announce the second Laupheimer Zelltage, a biennial industrial cell culture technology conference to be held on June 11-12, 2012 at Laupheim's historical castle, Schloss Großlaupheim. The aim of the Laupheimer Zelltage conferences is to provide comprehensive scientific updates on cutting-edge technologies and to discuss application-oriented topics as a means to advance protein and virus-based biologics production. The conference will bring together 200 academic and industrial experts on cell culture and process technology from all over the world. The official conference language is English.
The theme of the second Laupheimer Zelltage is “Bioprocess light”. The conference will focus on key factors that allow fast, robust, economically competitive processes. One of the sessions will be on “New Targets for Animal Cell Technology” with lectures covering increase of productivity (Dr. Martin Gawlitzek, Genentech Inc., San Francisco, USA), the prediction of productivity by gene expression analysis (Prof. Martin Clynes, Dublin City University, Ireland) and virus-based biologics as new product candidates (Dr. Markus Hörer, Rentschler Biotechnologie GmbH, Germany). The keynote lecture will be held by Prof. Manuel Carrondo (IBET, Portugal).
“Based on the success of the inaugural conference in 2010, we’ll keep the conference’s focus on the industrial aspects of cell culture technology. As one of the few conferences with this focus, the Laupheimer Zelltage is a vital opportunity to learn about trends and hear thoughtful inputs on mastering the challenges of industrial cell culture process development,” says Prof. Roland Wagner, Senior Vice President at Rentschler.
On June 11, before the first session of the conference, attendees will have the opportunity to visit Rentschler's new 1,000 L single-use facility that has been recently recognized with the 2012 Facility of the Year Award (FOYA) in the category ‘Equipment Innovation’.
About Rentschler Biotechnologie
Rentschler Biotechnologie GmbH is a global full-service contract manufacturer with more than 35 years of experience in the development, production and approval of biopharmaceuticals in compliance with international GMP standards (EMA/FDA). Rentschler Biotechnologie has nine GMP suites with volumes of 30, 50, 250, 500, 1,000 and 2,500 liters, allowing the production of material for clinical trials (phase I to III) and for market supply. Rentschler also provides regulatory advice, protein analytics, quality control, and the sterile filling of syringes and injection vials. The company is family-owned and independent and has currently about 650 employees.
Contact for more information about the conference:
Prof. Dr. Roland Wagner
Senior Vice President Development
Rentschler Biotechnologie GmbH
Phone: +49 7392 701-478